Fecal Transplant: How an Ancient Therapy Is Finding a New Use in Today’s Antibiotic-Resistant Era
Andrea McBeth, ND
Flora Medicine, Portland, OR, USA
Piper Dobner, ND, MS
Flora Medicine, Portland, OR, USA


Fecal microbiota transplant
Clostridium difficile
Antibiotic resistance


Fecal transplant refers to any method of delivery of healthy human stool to the colon of a recipient. This therapy is now gaining standard-of-care designation in the United States, Australia, and many parts of Europe for treating resistant Clostridium difficile infection). This literature review describes fecal transplant protocols. It highlights the variety of techniques used to screen stool donors; prepare and deliver treatment; and how, despite these variations, safety and efficacy remain high. It highlights the various ways to best mitigate safety while also recommending the direction in which clinical and research communities can move to continue to provide access to fecal microbiota transplant in a cost-effective manner.



1. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44:854–59.
2. Zhang F, Luo W, Shi Y, et al. Should we standardize the 1,700-year-old fecal microbiota transplantation. Am J Gastroenterol. 2012;107:1755.
3. Borody TJ, Warren EF, Leis SM, et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol. 2004;38:475–83.
4. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.
5. Chapman BC, Moore HB, Overbey DM, et al. Fecal microbiota transplant in patients with Clostridium difficile infection: a systematic review. J Trauma Acute Care Surg. 2016;81:756–64.
6. Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46:479–93.
7. Lai CY, Sung J, Cheng F, et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019;49:354–63.
8. Borody TJ, Connelly N, Mitchell SW. Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know Pol Arch Med Wewn. 2015;125:852–5.
9. U S Food and Drug Administration. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Fed Regist. 2016;78(138):42965–6. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota.
10. Sachs RE, Edelstein CA. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation. J Law Biosci. 2016;2:396–415. doi:10.1093/jlb/lsv032.
11. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011;9:88–96. doi:10.1038/nrgastro.2011.244.
12. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761–7. doi:10.1038/ajg.2011.482.
13. Krajicek E, Fischer M, Allegretti JR, Kelly CR. Nuts and bolts of fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2019;17:345–52. doi:10.1016/j.cgh.2018.09.029.
14. Lagier JC. Faecal microbiota transplantation: from practice to legislation before considering industrialization. Clin Microbiol Infect. 2014;20:1112–8. doi:10.1111/1469-0691.12795.
15. Lagier JC, Raoult D. Fecal microbiota transplantation: indications and perspectives [in French]. Med Sci (Paris). 2016;32:991–7. doi:10.1051/medsci/20163211015.
16. Jørgensen SMD, Erikstrup C, Dinh KM, et al. Recruitment of feces donors among blood donors: results from an observational cohort study. Gut Microbes. 2018;9:540–50. doi:10.1080/19490976.2018.1458179.
17. Vrieze A, De Groot PF, Kootte RS, et al. Fecal transplant: a safe and sustainable clinical therapy for restoring intestinal microbial balance in human disease? Best Pract Res Clin Gastroenterol. 2013;27:127–37. doi:10.1016/j.bpg.2013.03.003.
18. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044–9. doi:10.1016/j.cgh.2011.08.014.
19. Smith MB, Kelly C, Alm EJ. How to regulate faecal transplants. Nature. 2014;506:290–1. doi:10.1038/506290a.
20. US Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse. Published June 13, 2019. Accessed June 14, 2019.
21. Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review. Gut Microbes. 2017;8:225–37. doi:10.1080/19490976.2017.1286006.
22. Craven LJ, Nair Parvathy S, Tat-Ko J, et al. Extended screening costs associated with selecting donors for fecal microbiota transplantation for treatment of metabolic syndrome-associated diseases. Open Forum Infect Dis. 2017;4:ofx243. doi:10.1093/ofid/ofx243.
23. Hsu WH, Wang JY, Kuo CH. Current applications of fecal microbiota transplantation in intestinal disorders. Kaohsiung J Med Sci. 2019;35:327–31. doi:10.1002/kjm2.12069.
24. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66:1727–38.
25. Nagpal R, Mainali R, Ahmadi S, et al. Gut microbiome and aging: physiological and mechanistic insights. Nutr Healthy Aging. 2018;4:267–85.
26. Wang JW, Kuo CH, Kuo FC, et al. Fecal microbiota transplantation: review and update. J Formos Med Assoc. 2019;118(Suppl 1):S23–31. doi:10.1016/j.jfma.2018.08.011.
27. Choi HH, Cho YS. Fecal microbiota transplantation: current applications, effectiveness, and future perspectives. Clin Endosc. 2016;49:257–65. doi:10.5946/ce.2015.117.
28. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121:2126–32. doi:10.1172/JCI58109.2126.
29. Vrieze A, van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in subjects with metabolic syndrome. Gastroenterology. 2012;143:913–16.e7. doi:10.1053/j.gastro.2012.06.031.
30. Satokari R, Mattila E, Kainulainen V, Arkkila PET. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection – an observational cohort study. Aliment Pharmacol Ther. 2015;41:46–53. doi:10.1111/apt.13009.
31. Paramsothy S, Borody TJ, Lin E, et al. Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis. 2015;21:1600–6.
32. Palleja A, Mikkelsen KH, Forslund SK, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3:1255–65. doi:10.1038/s41564-018-0257-9.
33. Kim S, Jazwinski SM. The gut microbiota and healthy aging: a mini-review. Gerontology. 2018;64:513–20. doi:10.1159/000490615.
34. Cui B, Li P, Xu L, et al. Fecal microbiota transplantation is an effective rescue therapy for refractory inflammatory bowel disease. Inflamm Cell Signal. 2015;2:e757. doi:10.14800/ics.757.
35. de la Cuesta-Zuluaga J, Kelley ST, Chen Y, et al. Age- and sex-dependent patterns of gut microbial diversity in human adults. mSystems. 2019;4:e00261–19. doi:10.1128/msystems.00261-19.
36. Kim KO, Gluck M. Fecal microbiota transplantation: an update on clinical practice. Clin Endosc. 2019;52: 137–43. doi:10.5946/ce.2019.009.
37. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63.
38. Barnes D, Park KT. Donor considerations in fecal microbiota transplantation. Curr Gastroenterol Rep. 2017;19:10.
39. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–8. doi:10.1001/jama.2014.13875.
40. Kazerouni A, Burgess J, Burns LJ, Wein LM. Optimal screening and donor management in a public stool bank. Microbiome. 2015;3:75.
41. Defois C, Ratel J, Garrait G, et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep. 2018;8:11006. doi:10.1038/s41598-018-29376-9.
42. Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23:705–15. doi:10.1016/j.chom.2018.05.012.
43. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515–22. doi:10.1093/cid/ciu135.
44. Tang G, Yin W, Liu W. Is frozen fecal microbiota transplantation as effective as fresh fecal microbiota transplantation in patients with recurrent or refractory Clostridium difficile infection: a meta-analysis? Diagn Microbiol Infect Dis. 2017;88:322–9. doi:10.1016/j.diagmicrobio.2017.05.007.
45. Hamilton MJ, Weingarden AR, Unno T, et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013;4:125–35. doi:10.4161/gmic.23571.
46. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78:240–9. doi:10.1016/j.gie.2013.03.1329.
47. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002. doi:10.1093/cid/cir632.
48. Flores R, Shi J, Yu G, et al. Collection media and delayed freezing effects on microbial composition of human stool. Microbiome. 2015;3:33. doi:10.1186/s40168-015-0092-7.
49. Gorzelak MA, Gill SK, Tasnim N, et al. Methods for improving human gut microbiome data by reducing variability through sample processing and storage of stool. PLoS One. 2015;10:e0134802. doi:10.1371/journal.pone.0134802.
50. Jiang ZD, Alexander A, Ke S, et al. Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI). Anaerobe. 2017;48:110–4. doi:10.1016/j.anaerobe.2017.08.003.
51. Costello SP, Conlon MA, Vuaran MS, et al. Faecal microbiota transplant for recurrent Clostridium difficile infection using long-term frozen stool is effective: clinical efficacy and bacterial viability data. Aliment Pharmacol Ther. 2015;42:1011–8. doi:10.1111/apt.13366.
52. Kia E, MacKenzie BW, Middleton D, et al. Integrity of the human faecal microbiota following long-term sample storage. PLoS One. 2016;11:e0163666. doi:10.1371/journal.pone.0163666.
53. Hecker MT, Obrenovich ME, Cadnum JL, et al. Fecal microbiota transplantation by freeze-dried oral capsules for recurrent Clostridium difficile infection. Open Forum Infect Dis. 2016;3:ofw091. doi:10.1093/ofid/ofw091.
54. Staley C, Hamilton MJ, Vaughn BP, et al. Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study. Am J Gastroenterol. 2017;112(6):940–7.
55. Kelly CP, Lamont JT, Bakken JS. Clostridioides (formerly Clostridium) difficile infection in adults: treatment and prevention. UpToDate. April 2018.
56. Kao D, Roach B, Silva M, et al. Effect of oral capsule– vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318:1985–93. doi:10.1001/jama.2017.17077.
57. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–43. doi:10.1111/apt.13144.
58. Costello SP, Tucker EC, La Brooy J, et al. Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis. 2016;62:908–14. doi:10.1093/cid/civ994.
59. Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14:134. doi:10.1186/s12916-016-0680-9.
60. Edmond MB. The power of poop: fecal microbiota transplantation for Clostridium difficile infection. Trans Am Clin Climatol Assoc. 2016;127:71–80.
61. Brumbaugh DE, De Zoeten EF, Pyo-Twist A, et al. An intragastric fecal microbiota transplantation program for treatment of recurrent Clostridium difficile in children is efficacious, safe, and inexpensive. J Pediatr. 2018;194:123–7.e1. doi:10.1016/j.jpeds.2017.10.016.
62. Martinez C, Edwards J, Hassoun A. Commercialized fecal microbiota transplantation provides efficacious treatment of Clostridium difficile infection. Infect Dis (Auckl). 2018;50:864–7. doi:10.1080/23744235.2018.1500709.
63. Agrawal M, Aroniadis OC, Brandt LJ, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50:403–7.
64. Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review [published correction appears in PLoS One. 2014;9:e107420.]. PLoS One. 2014;9:e98400. doi:10.1371/journal.pone.0098400.
65. Duarte-Chavez R, Wojda TR, Zanders TB, et al. Early results of fecal microbial transplantation protocol implementation at a community-based university hospital. J Glob Infect Dis. 2018;10:47–57. doi:10.13040/IJPSR.0975-8232.7(6).2573-85.
66. Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623–8. doi:10.6084/m9.figshare.4813882.
67. Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol. 2014;30:97–105. doi:10.1097/MOG.0000000000000027.
68. Hirsch BE, Saraiya N, Poeth K, et al. Effectiveness of fecal-derived microbiota transfer using orally administered capsules for recurrent Clostridium difficile infection. BMC Infect Dis. 2015;15:191. doi:10.1186/s12879-015-0930-z.
69. Iqbal U, Anwar H, Karim MA. Safety and efficacy of encapsulated fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review. Eur J Gastroenterol Hepatol. 2018;30:730–4. doi:10.1097/MEG.0000000000001147.
70. Khan MY, Dirweesh A, Khurshid T, Siddiqui WJ. Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1309–17. doi:10.1097/MEG.0000000000001243.
71. Cheminet G, Kapel N, Bleibtreu A, et al. Faecal microbiota transplantation with frozen capsules for relapsing Clostridium difficile infections: the first experience from 15 consecutive patients in France. J Hosp Infect. 2018;100:148–51. doi:10.1016/j.jhin.2018.07.005.
72. Ooijevaar RE, Terveer EM, Verspaget HW, et al. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2018;70:335–51. doi:10.1146/annurev-med-111717-122956.
73. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015;162:630–8.
74. Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016;11:e0161174. doi:10.1371/journal.pone.0161174.
75. Rossen NG, MacDonald JK, De Vries EM, et al. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol. 2015;21:5359–71. doi:10.3748/wjg.v21.i17.5359.
76. Baxter M, Ahmad T, Colville A, Sheridan R. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis. 2015;61:136–7. doi:10.1093/cid/civ247.
77. Högenauer C, Kump PK, Krause R. Tempered enthusiasm for fecal transplantation? Clin Infect Dis. 2014;59:1348–9. doi:10.1093/cid/ciu567.
78. Singh R, van Nood E, Nieuwdorp M, et al. Donor feces infusion for eradication of extended spectrum β-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect. 2014;20:O977–8. doi:10.1111/1469-0691.12683.
79. Crum-Cianflone NF, Sullivan E, Ballon-Landa G. Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol. 2015;53:1986–9. doi:10.1128/JCM.00820-15.
80. Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065–71. doi:10.1038/ajg.2014.133.
81. Jalanka J, Hillamaa A, Satokari R, et al. The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2018;47:371–9. doi:10.1111/apt.14443.
82. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol. 2010;44:567–70. doi:10.1097/MCG.0b013e3181dadb10.
83. Moayyedi P, Yuan Y, Baharith H, Ford AC. Faecal microbiota transplantation for Clostridium difficile-associated diarrhoea: a systematic review of randomised controlled trials. Med J Aust. 2017;207:166–72.
84. Allegretti JR, Allegretti AS, Phelps E, et al. Classifying fecal microbiota transplantation failure: an observational study examining timing and characteristics of fecal microbiota transplantation failures. Clin Gastroenterol Hepatol. 2018;16:1832–3. doi:10.1016/j.cgh.2017.10.031.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.